GANX — Gain Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $60.62m
- $50.67m
Annual income statement for Gain Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.029 | 0.165 | 0.14 | 0.055 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Total Operating Expenses | 3.51 | 14 | 17.9 | 22.3 | 20.4 |
| Operating Profit | -3.48 | -13.8 | -17.8 | -22.3 | -20.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -3.57 | -13.9 | -17.5 | -22.2 | -19.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -3.58 | -13.9 | -17.6 | -22.3 | -20.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -3.58 | -13.9 | -17.6 | -22.3 | -20.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -3.58 | -13.9 | -17.6 | -22.3 | -20.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.316 | -1.37 | -1.48 | -1.71 | -0.892 |
| Dividends per Share |